Effects of Antibody Activation Duration on CD8+ T Cell Phenotype and Lentivirus Transduction Efficiency

Mei HUANG, Shiyu YANG, Sen LIN, Yongda LIU, Jihang YUAN

Life Sci Res ›› 2025, Vol. 29 ›› Issue (5) : 383-388.

Home Journals Life Science Research
Life Science Research

Abbreviation (ISO4): Life Sci Res      Editor in chief:

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
Life Sci Res ›› 2025, Vol. 29 ›› Issue (5) : 383-388. DOI: 10.16605/j.cnki.1007-7847.2025.03.0128
BASIC MEDICINE

Effects of Antibody Activation Duration on CD8+ T Cell Phenotype and Lentivirus Transduction Efficiency

Author information +
History +

Abstract

To investigate the effects of CD3/CD28 antibody activation duration on CD8+ T cell phenotype and lentiviral transduction efficiency, naïve CD8+ T cells were activated with CD3/CD28 antibodies for 24 h, 48 h, or 72 h. Phenotypic changes including cell proliferation status and the expression levels of surface molecules CD44, CD62L, and CD69 were detected by flow cytometry. The activated cells were then infected with lentivirus, and transduction efficiency at different activation time points was evaluated using both live-cell imaging and flow cytometry. The results showed that the proliferation rate of CD8+ T cells in the 24-hour group was significantly higher than that in the 48-hour and 72-hour groups. For surface molecule ex-pression, the expression level of CD44 in the 24-hour group was significantly higher than that in the non-activated group. When the activation duration extended to 48 h, CD44 expression was further significantly upregulated, but showed no significant difference to that in the 72-hour group. CD62L expression remained at a relatively high level before activation, and was slightly downregulated after 48 h of activation, but re-mained stable among the 0-hour, 24-hour, and 72-hour groups. The expression of CD69 in the 24-hour group was significantly higher than that in the non-activated group, but there was no significant difference a-mong the 24-hour, 48-hour, and 72-hour groups. For lentiviral transduction efficiency, both the 48-hour and 72-hour groups showed a significant decrease compared with the 24-hour group. This study demon-strates that 24 h is an ideal activation duration, substantially improving CD8+ T cell proliferation, activation level, and lentiviral transduction efficiency upon CD3/CD28 antibody stimulation.

Key words

CD3/CD28 antibodies / activation duration / CD8+ T cell / phenotype / lentivirus transduction

Cite this article

Download Citations
Mei HUANG , Shiyu YANG , Sen LIN , et al . Effects of Antibody Activation Duration on CD8+ T Cell Phenotype and Lentivirus Transduction Efficiency[J]. Life Science Research. 2025, 29(5): 383-388 https://doi.org/10.16605/j.cnki.1007-7847.2025.03.0128

References

[1]
CHOI H, KIM Y, JUNG Y W. The function of memory CD8+ T cells in immunotherapy for human diseases[J]. Immune Network, 2023, 23(1): e10.
[2]
KOK L, MASOPUST D, SCHUMACHER T N. The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues[J]. Nature Reviews Immunology, 2022, 22(5): 283-293.
[3]
MARTIN M D, BADOVINAC V P. Defining memory CD8 T cell[J]. Frontiers in Immunology, 2018, 9: 2692.
[4]
ZHANG N, BEVAN M J. CD8+ T cells: foot soldiers of the im-mune system[J]. Immunity, 2011, 35(2): 161-168.
[5]
FOSKOLOU I P, BARBIERI L, VERNET A, et al. The S enan-tiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome[J]. Blood Ad-vances, 2020, 4(18): 4483-4493.
[6]
MCLELLAN A D, ALI HOSSEINI RAD S M. Chimeric antigen receptor T cell persistence and memory cell formation[J]. Immu-nology and Cell Biology, 2019, 97(7): 664-674.
[7]
DEGOLIER K R, DANIS E, D′ANTONIO M, et al. Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response[J]. Nature Immunology, 2025, 26(1): 68-81.
[8]
DEMIRCAN M B, ZINSER L J, MICHELS A, et al. T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8[J]. Molecular Therapy, 2024, 32(10): 3470-3484.
[9]
MICHELS A, FRANK A M, GÜNTHER D M, et al. Lentiviral and adeno-associated vectors efficiently transduce mouse T lym-phocytes when targeted to murine CD8[J]. Molecular Therapy Methods & Clinical Development, 2021, 23: 334-347.
[10]
CHI H B, PEPPER M, THOMAS P G. Principles and therapeutic applications of adaptive immunity[J]. Cell, 2024, 187(9): 2052-2078.
[11]
CHEN L, QIAN W J, PAN F F, et al. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement[J]. Immunotherapy, 2024, 16(3): 143-159.
[12]
NATALINI A, SIMONETTI S, FAVARETTO G, et al. OMIP-079: cell cycle of CD4+ and CD8+ naïve/memory T cell subsets, and of Treg cells from mouse spleen[J]. Cytometry Part A: Jour-nal Quantitative Cell Science, 2021, 99(12): 1171-1175.
[13]
LI K Y, LIU C, SUI X Z, et al. An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer[J]. Cell Stem Cell, 2025, 32(8): 1218-1234.e1217.
[14]
BAEYENS A, BRACERO S, CHALUVADI V S, et al. Monocyte-derived S1P in the lymph node regulates immune responses[J]. Nature, 2021, 592(7853): 290-295.
[15]
SKOKOS D, WAITE J C, HABER L, et al. A class of costimu-latory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies[J]. Science Translational Medicine, 2020, 12(525): eaaw7888.
[16]
KERKAR S P, SANCHEZ-PEREZ L, YANG S C, et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies[J]. Journal of Immunotherapy, 2011, 34(4): 343-352.
[17]
FRANK A M, BRAUN A H, SCHEIB L, et al. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors[J]. Blood Advances, 2020, 4(22): 5702-5715.
[18]
LUOSTARINEN A, KAILAANMÄKI A, TURKKI V, et al. Opti-mizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing[J]. Cytotherapy, 2024, 26(9): 1084-1094.
[19]
JIMÉNEZ-FERNÁNDEZ M, RODRÍGUEZ-SINOVAS C, CAÑES L, et al. CD69-oxLDL ligand engagement induces programmed cell death 1 (PD-1) expression in human CD4+ T lymphocytes[J]. Cellular and Molecular Life Sciences, 2022, 79(8): 468.
[20]
CEBRIÁN M, YAÜGE E, RINCÓN M, et al. Triggering of T cell proliferation through AIM, an activation inducer molecule ex-pressed on activated human lymphocytes[J]. The Journal of Ex-perimental Medicine, 1988, 168(5): 1621-1637.
[21]
NAKAJIMA Y, CHAMOTO K, OURA T, et al. Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice[J]. Proceedings of the National Academy of Sciences of USA, 2021, 118(23): e2103730118.

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉